DrugBiological
Ficlatuzumab clinical trials
Also written AV-299.
- studies test it
- 12
- open now
- 2
- in phase 3
- 2
- first study started
- 2008
Keep track of what changes. Save the ficlatuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 6
AVEO Pharmaceuticals, Inc. (6) · Dana-Farber Cancer Institute (1) · James J Lee (1) · Beat AML, LLC (1) · C. Babis Andreadis (1) · Julie E. Bauman, MD, MPH (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Cytarabine (2) · Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Cetuximab (1) · Gefitinib (1) · Erlotinib (1) · Samalizumab (1)
Studies
Open first, then newest update. How each study uses ficlatuzumab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as ficlatuzumab (BAML-16-001-S24)
- A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaRecruitingPhase 3AVEO Pharmaceuticals, Inc.NCT06064877Written as Ficlatuzumab
- Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic CancerCompletedPhase 1Dana-Farber Cancer InstituteNCT03316599Written as Ficlatuzumab
- A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelTerminatedPhase 2AVEO Pharmaceuticals, Inc.NCT02318368Written as Ficlatuzumab
- A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnPhase 2AVEO Pharmaceuticals, Inc.NCT04100330Written as Ficlatuzumab
- Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AMLTerminatedPhase 1C. Babis AndreadisNCT02109627Written as Ficlatuzumab
- Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedPhase 1James J LeeNCT02277197Written as Ficlatuzumab
- Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 1Julie E. Bauman, MD, MPHNCT02277184Written as Ficlatuzumab
- A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung CancerCompletedPhase 1/2AVEO Pharmaceuticals, Inc.NCT01039948Written as AV-299 + gefitinib
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedPhase 1AVEO Pharmaceuticals, Inc.NCT00725634Written as AV-299
- A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver MetastasesCompletedPhase 1AVEO Pharmaceuticals, Inc.NCT00969410Written as AV-299
- SCH-900105 in Recurrent GlioblastomaWithdrawnPhase 1M.D. Anderson Cancer CenterNCT01189513Written as SCH 900105
Given in every arm · 1 — ficlatuzumab is usual care beside what is tested
Codes
What other systems call ficlatuzumab · ClinicalTrials.gg INT006343
- MeSH (NLM) C583360ficlatuzumabOne source NLM
- UNII (FDA) 77E89833TGFICLATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5446524FiclatuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78844FiclatuzumabOne source FDA
- DrugBank DB11680One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583360 | ficlatuzumab | One source NLM |
| UNII (FDA) | 77E89833TG | FICLATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5446524 | Ficlatuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78844 | Ficlatuzumab | One source FDA |
| DrugBank | DB11680 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.